Please assess the completion status of the following clinical trial:

Trial Title: MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Central pathology review submission; Note: this review for MART-1 positivity is mandatory prior to randomization to confirm eligibility~* Human leukocyte antigen (HLA)-A2-positive~* Histologic proof of stage II, III or IV melanoma that has been completely resected or completely treated with ablative therapy (ex: stereotactic body radiosurgery, radiofrequency ablation, cryoablation) with no current evidence of disease, as demonstrated by imaging within 2 months (stage III or stage IV; must be computed tomography \[CT\], magnetic resonance imaging \[MRI\], or positron emission tomography \[PET\]/CT) or 6 months (stage II; may be chest x-ray, CT, MRI, or PET/CT)~* Absolute neutrophil count (ANC) \>= 1500 mL~* Hemoglobin (Hgb) \> 10 g/dL~* Platelets (PLT) \>= 50,000 mL~* Aspartate aminotransferase (AST) =\< 3 x upper limit of normal (ULN)~* Alkaline phosphatase =\< 3 x ULN~* Ability to provide informed consent~* Willingness to return to Mayo Clinic Rochester for follow-up~* Life expectancy \>= 12 weeks~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2~* For women of childbearing potential, a negative serum pregnancy test =\< 7 days prior to registration~* Willingness to provide mandatory blood samples for correlative research~Exclusion Criteria:~* Uncontrolled or current infection~* Known standard therapy for the patient's disease that is potentially curative or proven capable of extending life expectancy~* Known allergy to any of the vaccine or adjuvant components, including eggs~* Any of the following prior therapies with interval since most recent treatment:~  * Chemotherapy =\< 4 weeks prior to registration~ * Biologic or immunologic therapy =\< 4 weeks prior to registration~ * Radiation therapy =\< 4 weeks prior to registration~* Failure to fully recover from side effects of prior therapy or surgery~* Any of the following:~  * Pregnant women~ * Nursing women~ * Women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device \[IUD\], surgical sterilization, subcutaneous implants, or abstinence, etc.)~* Known immune deficiency, including human immunodeficiency virus (HIV) infection~* History of systemic autoimmune disease, as patients with ongoing autoimmunity may be at an increased risk of autoimmune toxicity from the study vaccine~* Current or recent (=\< 4 weeks) use of immunosuppressive medications including systemic (inhaled, oral, or intravenous \[IV\]) corticosteroids; Note: use of corticosteroids in doses not exceeding those used for adrenal replacement is acceptable~* History of brain metastases; EXCEPTION: patients with a solitary brain metastasis that has been completely resected, and who have no ongoing central nervous system (CNS) symptoms and an MRI documenting no evidence of CNS disease at least 3 months after resection and within 30 days of registration, are eligible for treatment~* Other active malignancy =\< 5 years prior to registration; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a history of prior malignancy \> 5 years prior to registration, the patient must not be receiving other cancer treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (MART-1 antigen and TLR4 antagonist GLA-SE) (Type: EXPERIMENTAL): Patients receive MART-1 antigen and TLR4 antagonist GLA-SE IM on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
- Arm II (MART-1 antigen) (Type: EXPERIMENTAL): Patients receive MART-1 antigen IM on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete